Follow
Robert A Beckman
Robert A Beckman
Professor of Oncology & of Biostatistics, Bioinformatics, & Biomathematics, Georgetown University
Verified email at georgetown.edu
Title
Cited by
Cited by
Year
Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors
RA Beckman, LM Weiner, HM Davis
Cancer 109 (2), 170-179, 2007
4172007
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
I Krop, T Demuth, T Guthrie, PY Wen, WP Mason, P Chinnaiyan, ...
Journal of clinical oncology 30 (19), 2307-2313, 2012
3412012
On the fidelity of DNA replication: manganese mutagenesis in vitro
RA Beckman, AS Mildvan, LA Loeb
Biochemistry 24 (21), 5810-5817, 1985
3151985
Cancers exhibit a mutator phenotype: clinical implications
LA Loeb, JH Bielas, RA Beckman
Cancer research 68 (10), 3551-3557, 2008
2602008
Interaction of the RNA‐binding domain of the hnRNP C proteins with RNA.
M Görlach, M Wittekind, RA Beckman, L Mueller, G Dreyfuss
The EMBO journal 11 (9), 3289-3295, 1992
2561992
Genetic instability in cancer: theory and experiment
RA Beckman, LA Loeb
Seminars in cancer biology 15 (6), 423-435, 2005
1842005
Solution structure of horse heart ferricytochrome c and detection of redox-related structural changes by high-resolution 1H NMR
PX Qi, RA Beckman, AJ Wand
Biochemistry 35 (38), 12275-12286, 1996
1661996
Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors
SA Mullamitha, NC Ton, GJM Parker, A Jackson, PJ Julyan, C Roberts, ...
Clinical Cancer Research 13 (7), 2128-2135, 2007
1632007
Identification of a local anesthetic binding site in nicotinic post-synaptic membranes isolated from Torpedo marmorata electric tissue
EK KRODEL, RA BECKMAN, JB COHEN
Molecular pharmacology 15 (2), 294-312, 1979
1601979
On the fidelity of DNA replication. Effect of the next nucleotide on proofreading.
TA Kunkel, RM Schaaper, RA Beckman, LA Loeb
Journal of Biological Chemistry 256 (19), 9883-9889, 1981
1321981
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid …
F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ...
Clinical Cancer Research 17 (19), 6304-6312, 2011
1302011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid …
F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ...
Clinical Cancer Research 17 (19), 6304-6312, 2011
1302011
Integrating predictive biomarkers and classifiers into oncology clinical development programmes
RA Beckman, J Clark, C Chen
Nature Reviews Drug Discovery 10 (10), 735-748, 2011
1252011
Alpha-v integrins as therapeutic targets in oncology
JA Nemeth, MT Nakada, M Trikha, Z Lang, MS Gordon, GC Jayson, ...
Cancer investigation 25 (7), 632-646, 2007
1182007
A roadmap to using historical controls in clinical trials–by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)
M Ghadessi, R Tang, J Zhou, R Liu, C Wang, K Toyoizumi, C Mei, ...
Orphanet Journal of Rare Diseases 15 (1), 1-19, 2020
1172020
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer
M Gore, A Oza, G Rustin, J Malfetano, H Calvert, D Clarke-Pearson, ...
European Journal of Cancer 38 (1), 57-63, 2002
1142002
Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer
RA Beckman, GS Schemmann, CH Yeang
Proceedings of the National Academy of Sciences 109 (36), 14586-14591, 2012
1102012
Efficiency of carcinogenesis with and without a mutator mutation
RA Beckman, LA Loeb
Proceedings of the National Academy of Sciences 103 (38), 14140-14145, 2006
1092006
Efficiency of carcinogenesis with and without a mutator mutation
RA Beckman, LA Loeb
Proceedings of the National Academy of Sciences 103 (38), 14140-14145, 2006
1092006
Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy …
A Forero‐Torres, JR Infante, D Waterhouse, L Wong, S Vickers, ...
Cancer medicine 2 (6), 925-932, 2013
1072013
The system can't perform the operation now. Try again later.
Articles 1–20